Praluent Lives On As US Court Vacates Amgen's PCSK9 Patent Win
While sales of Sanofi/Regeneron's Praluent, which will remain on the US market for the time being, could see a small boost, larger commercial challenges in the PCSK9 category linger.
You may also be interested in...
Amgen ended its own development of the CETP inhibitor AMG 899, but will see if anyone else wants to license the drug. Meanwhile, the company is focusing on new drugs and assets in development to offset declining sales for Enbrel and other blockbusters.
There's optimism around Novartis as it heads into its final quarter with Joe Jimenez in charge, while Lilly faces impending headwinds, GSK will be touting Shingrix for future growth as vaccines growth tempers, and Amgen treads a complicated path through the biosimilar landscape.
Federal Circuit stays injunction that would have halted sales of the PCSK9 inhibitor on Feb. 21; stay extends through appeal of injunction and patent verdict.